$TTPH Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
– Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a ‘Best Rated Abstract’ –
– Other Key Eravacycline and TP-6076 Data to Also be Highlighted –
WATERTOWN, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced six data presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 21-24 in Madrid, Spain at the IFEMA – Feria de Madrid. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is in development for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, the lead candidate under its second-generation program to target MDR Gram-negative bacteria.
“We are pleased to present data from the IGNITE4 study, which garnered a ‘Best Rated Abstract’ designation at this year’s ECCMID Congress,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals. “In addition, we will share findings from a large-scale surveillance study conducted by the International Health Management Associates in Europe, in which eravacycline demonstrated potent in vitro activity against more than 1,550 multidrug-resistant isolates of clinically significant Gram-negative and Gram-positive organisms collected globally. We believe these data further support the clinical profile of eravacycline in treating serious and life-threatening infections and look forward to the Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2018 for eravacycline.”
Mr. Macdonald adds, “Further, we are encouraged by data demonstrating the in vitro activity of TP-6076. In a study of more than 100 isolates from hospitals in Greece, TP-6076 exhibited greater antimicrobial activity against carbapenem-resistant Acinetobacter baumannii than comparator antibiotics, thereby supporting our commitment to developing this pipeline asset for MDR Gram-negative infections.”
Larry Tsai, M.D., Chief Medical Officer of Tetraphase, stated “I’m pleased to be presenting IGNITE4 data which demonstrate high clinical cure rates in patients with cIAI comparable to meropenem. These data are instrumental in our belief that eravacycline offers a clear advantage to carbapenems in cases where Gram-negative resistance is a concern. We look forward to sharing these important data with the medical community at ECCMID this year.”
The details for the data presentations at ECCMID are as follows:
Eravacycline oral presentation – A ‘Best Rated Abstract’
Presentation title: Results of IGNITE4: a phase-3 study to evaluate the efficacy and safety of eravacycline versus meropenem in complicated intra-abdominal infections
Date and time: Sunday, April 22 from 11:30a.m. – 12:00p.m. CEST
Location: Hall Q
Presentation number: #O0421
Speaker: Larry Tsai, M.D.
Session information: Snapshot on pre-registration clinical trials
Eravacycline poster presentations
Poster Title: In vitro activity of eravacycline and comparators against resistant Gram-negative isolates collected in 2016 from patients in Europe
Date and time: Saturday, April 21 from 3:30 – 4:30 p.m. CEST
Location: Paper Poster Arena
Poster number: #P0099
Session information: Activity of new or re-purposed non-beta lactam drugs against Gram-negatives
Poster title: Eravacycline in vitro activity against European clinical isolates obtained in 2016 from urinary and gastrointestinal sources, including drug resistant pathogens
Date and time: Saturday, April 21 from 3:30 – 4:30 p.m. CEST
Location: Paper Poster Arena
Poster number: #P0100
Session information: Activity of new or re-purposed non-beta lactam drugs against Gram-negatives
Poster Title: Global surveillance of in vitro activity of eravacycline and comparators against Enterobacteriaceae, Stenotrophomonas maltophilia, Staphylococcus aureus and Enterococcus spp. collected during 2016
Date and time: Saturday, April 21 from 3:30 – 4:30 p.m. CEST
Location: Paper Poster Arena
Poster number: #P0101
Session information: Activity of new or re-purposed non-beta lactam drugs against Gram-negatives
– Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a ‘Best Rated Abstract’ –
– Other Key Eravacycline and TP-6076 Data to Also be Highlighted –
WATERTOWN, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced six data presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 21-24 in Madrid, Spain at the IFEMA – Feria de Madrid. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is in development for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, the lead candidate under its second-generation program to target MDR Gram-negative bacteria.
“We are pleased to present data from the IGNITE4 study, which garnered a ‘Best Rated Abstract’ designation at this year’s ECCMID Congress,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals. “In addition, we will share findings from a large-scale surveillance study conducted by the International Health Management Associates in Europe, in which eravacycline demonstrated potent in vitro activity against more than 1,550 multidrug-resistant isolates of clinically significant Gram-negative and Gram-positive organisms collected globally. We believe these data further support the clinical profile of eravacycline in treating serious and life-threatening infections and look forward to the Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2018 for eravacycline.”
Mr. Macdonald adds, “Further, we are encouraged by data demonstrating the in vitro activity of TP-6076. In a study of more than 100 isolates from hospitals in Greece, TP-6076 exhibited greater antimicrobial activity against carbapenem-resistant Acinetobacter baumannii than comparator antibiotics, thereby supporting our commitment to developing this pipeline asset for MDR Gram-negative infections.”
Larry Tsai, M.D., Chief Medical Officer of Tetraphase, stated “I’m pleased to be presenting IGNITE4 data which demonstrate high clinical cure rates in patients with cIAI comparable to meropenem. These data are instrumental in our belief that eravacycline offers a clear advantage to carbapenems in cases where Gram-negative resistance is a concern. We look forward to sharing these important data with the medical community at ECCMID this year.”
The details for the data presentations at ECCMID are as follows:
Eravacycline oral presentation – A ‘Best Rated Abstract’
Presentation title: Results of IGNITE4: a phase-3 study to evaluate the efficacy and safety of eravacycline versus meropenem in complicated intra-abdominal infections
Date and time: Sunday, April 22 from 11:30a.m. – 12:00p.m. CEST
Location: Hall Q
Presentation number: #O0421
Speaker: Larry Tsai, M.D.
Session information: Snapshot on pre-registration clinical trials
Eravacycline poster presentations
Poster Title: In vitro activity of eravacycline and comparators against resistant Gram-negative isolates collected in 2016 from patients in Europe
Date and time: Saturday, April 21 from 3:30 – 4:30 p.m. CEST
Location: Paper Poster Arena
Poster number: #P0099
Session information: Activity of new or re-purposed non-beta lactam drugs against Gram-negatives
Poster title: Eravacycline in vitro activity against European clinical isolates obtained in 2016 from urinary and gastrointestinal sources, including drug resistant pathogens
Date and time: Saturday, April 21 from 3:30 – 4:30 p.m. CEST
Location: Paper Poster Arena
Poster number: #P0100
Session information: Activity of new or re-purposed non-beta lactam drugs against Gram-negatives
Poster Title: Global surveillance of in vitro activity of eravacycline and comparators against Enterobacteriaceae, Stenotrophomonas maltophilia, Staphylococcus aureus and Enterococcus spp. collected during 2016
Date and time: Saturday, April 21 from 3:30 – 4:30 p.m. CEST
Location: Paper Poster Arena
Poster number: #P0101
Session information: Activity of new or re-purposed non-beta lactam drugs against Gram-negatives
Tetraphase Pharmaceuticals Inc. (TTPH) Stock Research Links
Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
